Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.00    -0.50 (-0.75%)
Bid:
65.00
Ask:
67.00
Spread: 2.00 (3.077%)
Market Cap: £80.07m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

Today 15:03

RNS Number : 4429K
Venture Life Group PLC
30 June 2026
 

30 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, has today purchased 93,887 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a volume-weighted average price of 63.9 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,145,985 Ordinary Shares representing approximately 0.89 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)

 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Paul McGreevy

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

63.875 pence

31,297

63.875 pence

31,297

63.850 pence

15,650

63.880 pence

15,643

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

93,887 Ordinary Shares purchased at a volume-weighted average price of 63.9 pence.

 

 

e)

 

Date of the transaction

 

30 June 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFISRLIIVIR
Date   Source Headline
13th Feb 20263:07 pmRNSHolding(s) in Company
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20265:40 pmRNSPCA Dealing
12th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20264:30 pmRNSTotal Voting Rights
30th Jan 20264:42 pmRNSExercise of Share Options & Total Voting Rights
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:30 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTrading Update
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSExercise of Share Options & Total Voting Rights
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 202611:27 amRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20264:30 pmRNSTotal Voting Rights
2nd Jan 20267:00 amRNSExercise of Options, Director Dealings & TVR
2nd Jan 20267:00 amRNSExercise of Options, Director Dealings & TVR
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
24th Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20254:18 pmRNSExercise of Share Options & Total Voting Rights
18th Dec 20254:18 pmRNSExercise of Share Options & Total Voting Rights
17th Dec 20254:21 pmRNSHolding(s) in Company
17th Dec 20254:19 pmRNSHolding(s) in Company
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.